Sign in

NCT07428447Recruiting

Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease

Source: ClinicalTrials.gov · Last updated 22 Oct 2026

Brief summary (registry, in English)

Background and Rationale Essential tremor (ET) affects over 6 million Americans and approximately 5% of adults over age 60. Patients with ET have a 10-20 times higher risk of developing Parkinson's disease (PD) compared to age-matched populations, with approximately 1% converting to PD annually. Post-mortem studies reveal Lewy body pathology in some ET patients, suggesting a subset may have prodromal PD. Current diagnostic tools (DaTscan, SYNTap) are either insufficiently sensitive for early disease, too expensive, or too invasive for routine screening. The Syn-One Test offers a minimally invasive approach to detect phosphorylated α-synuclein (P-SYN) pathology in skin biopsies. Primary Objectives 1. Identify which ET patients have P-SYN pathology indicative of prodromal PD 2. Predict which patients are most likely to phenoconvert to PD

Status (registry)
Recruiting
Study type
Observational
Enrollment
300 (estimated)
First submitted
13 Feb 2026
Start date
18 Feb 2026
Primary completion date
28 Feb 2027
Lead sponsor
CND Life Sciences
NCT number
NCT07428447

What you commit to

  • Study type: Observational
  • Planned participants: 300
  • From 18 Feb 2026 to the primary completion date, 28 Feb 2027
  • 8 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Participant is currently receiving treatment with carbidopa-levodopa for PD
  • Prior to enrollment, receipt of an intracranial procedure intended to treat tremor or parkinsonism, including thalamic deep brain stimulation (DBS) implantation or focused ultrasound (FUS) thalamotomy. Other prior intracranial surgery is exclusionary only when, in the investigator's or Sponsor's Chief Medical Officer's judgment, it could materially affect motor assessments, diagnostic classification, participant safety, or interpretation of study outcomes.

Other illness

  • Clinical evidence of severe peripheral vascular disease
  • Clinically active coronary artery or cerebrovascular disease
  • Allergic reaction to local anesthesia
  • History of or increased risk for impaired wound healing, scarring, or keloid formation
  • History of other neurodegenerative disorder or evidence of neurological co-pathology

Lab values

  • Participant is currently on anticoagulant or dual anti-platelet therapy

Age

  • Under age 50, Over age 85

Other

  • Alcoholism
  • Diagnosis of ET or ET-Plus that is clinically determined to likely be secondary to brain injury or vascular compromise
  • Abnormal DaTscan
  • Isolated focal tremors (head, voice)
  • Task-specific tremor (e.g., primary writing tremor)
  • Position-specific tremors that does not otherwise meet clinical diagnostic criteria for ET
  • Sudden onset and step-wise deterioration

Who the study is looking for

  • Age 50-85 years old
  • Diagnosis of ET as defined by the 2018 MDS Task force paper "1) isolated tremor syndrome of bilateral upper limb action tremor 2) at least 3 years' duration 3) with or without tremor in other locations (e.g., head, voice, or lower limbs) 4) absence of other neurological signs, such as dystonia, ataxia, or parkinsonism." OR
  • Diagnosis of ET-Plus as stated by the 2018 MDS Task force paper, "Tremor with the characteristics of ET and additional neurological signs of uncertain significance such as impaired tandem gait, questionable dystonic posturing, memory impairment, or other mild neurologic signs of unknown significance that do not suffice to make an additional syndrome classification or diagnosis. ET with tremor at rest should be classified here."
  • Willing to participate in all study procedures
  • Able and willing to provide written informed consent

Age in the registry: 50 years to 85 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (8)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
QUEST Research Institute
Coordinator of this site? Confirm its status
Farmington HillsUnited StatesRecruiting
University of Kansas Medical Center
Coordinator of this site? Confirm its status
Kansas CityUnited StatesNot yet recruiting
Norton Healthcare
Coordinator of this site? Confirm its status
LouisvilleUnited StatesRecruiting
Veracity Neurosciences LLC
Coordinator of this site? Confirm its status
MemphisUnited StatesRecruiting
Vanderbilt University Medical Center
Coordinator of this site? Confirm its status
NashvilleUnited StatesNot yet recruiting
Neurology One
Coordinator of this site? Confirm its status
OrlandoUnited StatesRecruiting
CND Clinical Research Center
Coordinator of this site? Confirm its status
ScottsdaleUnited StatesRecruiting
Movement Disorders Center of Arizona
Coordinator of this site? Confirm its status
ScottsdaleUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.